USFDA approves Bayer’s darolutamide for Prostate Cancer.
Hello friends today is august 4th 2019 and this video contains information on recent approvals of new pharmaceutical medicines by us food and drug administration before moving to further information if you learn something or if you find information provided in this video as helpful please motivate us by subscribing liking and sharing this video us fda approves
Bayers darryl utam id for prostate cancer us food & drug administration has approved new prostate cancer drug darryl laura might darryl utam id is a non-steroidal anti androgen specifically a selective antagonist of the androgen receptor the us food and drug administration has approved darryl utam id under the brand name new abeka for the treatment of patients
With non-metastatic castration resistant prostate cancer fda approved samsung bio epi is head lama fourth humor avaya similar helio reports the fda has approved the fourth by a similar to adalimumab for all eligible indications of the biologic product head lama of samsung bio epi abhaya similar to chimera is a tnf inhibitor intended to treat patients with rheumatoid
Arthritis juvenile idiopathic arthritis psoriatic arthritis ankylosing spondylitis adult crohn’s disease ulcerative colitis and plaque psoriasis pad lemma is the fourth by a similar to kimura to gain fda approval in the united states following her amma’s of sandoz in 2018 salt is o of burner ingelheim in 2017 and m javita of m gen in 2016 situs canola has received
Final approval for acne drug from fda situs khatola has received final approval from the us health regulator to market minocycline hydrochloride extended-release tablets used to treat acne as canola said in a bsc filing on august 2nd 2019 minocycline hydrochloride extended-release tablets are indicated to treat only inflammatory lesions of non-modular moderate to
Severe acne vulgaris in patients of 12 years of age or older us fda approves daya chi sankyo ster a leo for rare joint tumor reuters reported that the us food and drug administration on friday approved daya chi san jose treatment for adult patients with a debilitating rare condition called tenno synovial giant cell tumor which is a non cancerous tumor affecting
Joints and limbs the label for the treatment to rally au includes a boxed warning flagging the risk of serious and potentially fatal liver injury to rally au is the first approved therapy in the united states for ten au synovial giant cell tumor the primary treatment of which has so far been surgery thank you for watching this video if you still not subscribe to
My channel please subscribe for more such videos if you have any comments or questions please write in comments section please share this video with your friends and do not forget to hit the like button
Transcribed from video
Pharma, life science and medical news Aug 1st week By D̷O̷S̷E̷S̷ O̷F̷ V̷I̷D̷E̷O̷S̷
